Zobrazeno 1 - 10
of 47
pro vyhledávání: '"J R Eckardt"'
Publikováno v:
Lung Cancer. 41:S37-S41
In a case study-based workshop, physicians were asked to discuss various aspects of patient management in small cell lung cancer (SCLC). For first-line chemotherapy, most investigators recommended treatment with etoposide/cisplatin, with possible dos
Autor:
J R Eckardt
Publikováno v:
Oncology. 61:42-46
The single-agent activity of intravenous (i.v.) topotecan has been established in small-cell lung cancer (SCLC), with overall tumor responses of 39% in previously untreated patients and 11–37% in relapsed patients. An oral formulation of topotecan
Autor:
J R Eckardt
Publikováno v:
American Journal of Health-System Pharmacy. 54:S2-S6
The mechanism of action, cellular uptake, cytotoxicity, use in drug combinations, resistance profile, and toxicology of docetaxel are reviewed. Docetaxel acts by stabilizing microtubules--enhancing the rate and extent of tubulin polymerization, and i
Autor:
G. J. Creemers, J R Eckardt, Gladys Rodriguez, H. A. Burris, C. Broom, Walter J. Loos, D. D. Von Hoff, Jaap Verweij, I. Hudson, A. S. T. Planting, C. J. H. Gerrits, J.H.M. Schellens
Publikováno v:
Journal of Clinical Oncology. 15:1087-1093
PURPOSE Topotecan is a specific inhibitor of topoisomerase I. Recently bioavailability of an oral formulation of approximately 30% with limited variability was reported. We conducted a phase I and pharmacokinetic study of the oral formulation of topo
Autor:
J R Eckardt
Publikováno v:
Anti-Cancer Drugs. 7:41-46
Autor:
J R Eckardt, David Rinaldi, C DeMoor, C. D. Stephens, D. D. Von Hoff, G. I. Rodriguez, Geoffrey R. Weiss, Don W. Shaffer
Publikováno v:
Anti-Cancer Drugs. 7:402-409
The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare t
Autor:
Howard A. Burris, J R Eckardt, J Jenkins, Geoffrey R. Weiss, S. S. Legha, Agop Y. Bedikian, Omar Eton, D. D. Von Hoff, L Smetzer, Antonio C. Buzaid
Publikováno v:
Journal of Clinical Oncology. 13:2895-2899
PURPOSE A phase II study was undertaken to determine the efficacy of docetaxel in patients with metastatic malignant melanoma. PATIENTS AND METHODS Between June 1992 and March 1994, 40 patients with metastatic malignant melanoma and no prior chemothe
Autor:
Patrick W. Cobb, L Smith, J. G. Kuhn, Ahmad Awada, D. D. Von Hoff, J R Eckardt, D A Rinaldi, Howard A. Burris, S. Fields
Publikováno v:
Anti-Cancer Drugs. 5:394-402
Topotecan (SKF 104864-A, NSC 609699) is a water-soluble, semi-synthetic analog of camptothecin which is an inhibitor of topoisomerase I. Since topoisomerase I is cell specific for S phase, we undertook a phase I study to determine the maximum tolerat
Autor:
Chandra P. Belani, J R Eckardt
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 46
Docetaxel, a semisynthetic taxane initially developed for the treatment of breast cancer, has a high degree of activity in lung cancer. Although the mechanisms of action of the taxanes docetaxel and paclitaxel are identical, docetaxel has almost a tw
Autor:
J R Eckardt
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 41
The survival and quality of life benefits of combination chemotherapy in patients with non-small cell lung cancer (NSCLC) are now well recognized. Since many clinical trials have been conducted in relatively young patients with good performance statu